Ozmosi | Levosulpiride Drug Profile

Product Description

Mechanisms of Action: D2 Blocker

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral,Intramuscular

FDA Designation: *

Approval Status: Not Approved

Approved Indications: None

Known Adverse Events: None

Company: Carmen Clapp
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Schizophrenia|Psychomotor Agitation

Phase 2: Depressive Disorder|Schizophrenia|Dyspepsia|Diabetic Retinopathy|Macular Edema

Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
LDRDME_247164	P2	Recruiting	Macular Edema\|Diabetic Retinopathy	2025-12-01	2024-12-07	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
EC/07/17/1202	N/A	Completed	Helicobacter Infections\|Dyspepsia	2019-05-31	2021-01-14	Primary Endpoints\|Treatments
CTR20181791	N/A	Completed	Healthy Volunteers	2018-09-04	2025-04-29	Patient Enrollment\|Treatments
CTR20132118	P2	Completed	Unknown	2015-03-12	2025-04-29	Patient Enrollment\|Treatments
CTR20150181	P2	Completed	Dyspepsia	2014-02-25	2025-04-29	Patient Enrollment\|Treatments
CTR20131994	P1	Completed	Sensation Disorders\|Chronic Pain\|Migraine Disorders\|Schizophrenia\|Visceral Pain\|Heartburn\|Headache Disorders, Primary\|Constipation\|Anorexia\|Hemiplegia\|Diarrhea\|Depressive Disorder\|Acute Pain\|Gastroparesis\|Abdominal Pain	2014-02-07	2025-04-29	Patient Enrollment\|Treatments
WHXH-Levosul	P1	Completed	Dyspepsia	2013-05-01	2019-03-20	Treatments
2004L03556	P3	Completed	Schizophrenia\|Psychomotor Agitation	2010-07-01	2019-03-18	Treatments
CTR20160303	P2	Not yet recruiting	Depressive Disorder\|Schizophrenia	None	2025-04-29

Recent News Events

Date	Type	Title
03/20/2024	PubMed	Dopaminergic Drugs and Valproate-associated Refractory Hyponatremia Over Levosulpiride-induced Parkinsonism in an Elderly Female Patient When Deprescribing was the Only Therapy.
01/01/2024	PubMed	Fixed drug combination (levosulpiride and rabeprazole)-induced atypical Parkinsonian's disorders with associated anxiety and low-lying depression.
09/02/2023	News Article	This report provides a comprehensive analysis of the Cancer Pain market's current state and future growth potential, with a projected CAGR of 4.4% over the forecast period 2023 to 2030.
09/02/2023	News Article	Strontium Chloride Hexahydrate Market Trends identifies the leading companies and provides analysis of key factors influencing t 4% CAGR Forecasted from 2023 to 2030
09/02/2023	News Article	The Levosulpiride market report's foreign opportunities and dynamics analysis delves into the market's size, which is projected to grow at a CAGR of 8.5% from 2023 to 2030, and provides an overview of revenue generation, COVID-19 impact, and application.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Levosulpiride

Alternative Names: levosulpiride Clinical Status: Inactive Latest Update: 2024-12-06 Latest Update Note: Clinical Trial Update